Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001104659-25-048597
Filing Date
2025-05-14
Accepted
2025-05-14 17:00:43
Documents
2

Document Format Files

Seq Description Document Type Size
1 424B3 tm2515104d1_424b3.htm 424B3 42546
2 GRAPHIC image_001.jpg GRAPHIC 6980
  Complete submission text file 0001104659-25-048597.txt   53434
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 424B3 | Act: 33 | File No.: 333-285438 | Film No.: 25946872
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)